A Univariate Analysis of Factors Influencing Survival in Advanced Pancreatic Neuroendocrine Tumors Abstract #1403

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare and display clinical heterogeneity.
Aim(s): We propose a clinical risk stratification tool for well differentiated, metastatic pNET.
Materials and methods: Retrospective study using clinical, pathological and laboratory variables for univariate analyses in a consecutive multicenter cohort (N=312) with pathologically confirmed, sporadic, well differentiated (grade 1 or 2), metastatic (Stage IV) pNET diagnosed between 1993 and 2010 with a minimum follow-up of 5 years. Data are presented as the mean with standard deviation (SD) and/or 95% confidence interval (CI). Overall survival was calculated using the Kaplan-Meier method with log-rank testing for potentially prognostic factors.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Henning Jann
Keywords: pNET, prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1361 Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor
Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Sebastian Krug
Keywords: pNET
#663 Comparing Chinese Pancreatic Neuroendocrine Tumors with Americans: Their Clinicopathological Features and Prognosis
Introduction: It is unknown if clin-patho features of PNET pts are different between China and USA, the largest country in the east and west, respectively.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr. X.W. Qiao
Authors: Qiao X W, Tang L, Zhu L M, Chen J, ...
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#1076 “Wait and Watch” Approach for Small Pancreatic Neuroendocrine Tumors (pNETs): Prognosis and Survival in 51 Consecutive Patients.
Introduction: The most appropriate management for small non-functioning pancreatic neuroendocrine tumors (pNETs) is lacking and whether all these lesions should be routinely resected is still debatable
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Roberta Elisa Rossi
#1161 Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors
Introduction: Insulinoma is the most common functional PNET. Its molecular tumorigenesis is largely unknown and proteomic study on insulinoma has not been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Qiao X W, Song Y L, Bai C M, Zhu L M, ...
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.